New Test **3000082** **Antinuclear Antibody (ANA) with HEp-2 Substrate, IgG by IFA** **ANA IFA AB**

Additional Technical Information

Methodology: Semi-Quantitative Indirect Fluorescent Antibody
Performed: Sun-Sat
Reported: 1-3 days

Specimen Required: Collect: Serum Separator Tube (SST).
Specimen Preparation: Separate from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.15 mL)
Storage/Transport Temperature: Refrigerated.
Unacceptable Conditions: Plasma. Contaminated, hemolyzed, or severely lipemic specimens.
Stability (collection to initiation of testing): After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)

Reference Interval: Less than 1:80

Interpretive Data: Presence of antinuclear antibodies (ANA) is a hallmark feature of systemic autoimmune rheumatic diseases (SARD). ANA lacks diagnostic specificity and is associated with a variety of diseases (cancers, autoimmune, infectious, and inflammatory conditions) and may also occur in healthy individuals in varying prevalence. The lack of diagnostic specificity requires confirmation of positive ANA by more-specific serologic tests. Diagnosis may be aided by the pattern(s) observed.

Negative results do not necessarily rule out SARD.

Note: ANA are determined by indirect fluorescence assay (IFA) using HEp-2 substrate and IgG-specific conjugate at a screening dilution of 1:80. If positive, patterns reported include homogeneous, speckled, centromere, nucleolar, nuclear dots, or cytoplasmic. All positive results are reported with endpoint titers.

CPT Code(s): 86039

New York DOH Approved.

HOTLINE NOTE: Refer to the Test Mix Addendum for interface build information.